AnaptysBio (NASDAQ:ANAB) has slipped 13.5% postmarket after posting some positive topline data from its interim analysis of the GALLOP Phase 2 clinical trial.
That analysts was conducted with the first two
patients completing a 16-week ANB019 monotherapy study for treating
moderate-to-severe generalized pustular psoriasis.
That’s a chronic, life-threatening, rare inflammatory disease that has no approved therapies, the company says.
Enrollment is ongoing and the company expects additional clinical data and a regulatory strategy update in 2020.
https://seekingalpha.com/news/3502749-anaptysbio-minus-13_5-percent-gallop-trial-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.